At a median follow-up of 39.4 months, results from the second interim analysis showed a sustained and significant OS benefit with BVd compared to DVd.

Nektar Therapeutics still needs to establish what differentiates rezpeg from other atopic dermatitis therapies, according to ...

The approval was based on the TRuE-AD3 trial, which evaluated the safety and efficacy of ruxolitinib in pediatric patients aged 2 to 11 years with atopic dermatitis.

On Thursday, Sanofi SA (NASDAQ:SNY) stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, ...

Subcutaneous daratumumab with lenalidomide significantly increased MRD-negative conversion rates compared to lenalidomide ...

As people grow older, the chances of their having multiple comorbidities rise. But ageing also marks a phase in life when there is loss of income or a higher dependency on family for financial support ...

Monte Rosa Therapeutics stock surged after expanding its Novartis partnership. Click here to learn about their innovative pipeline and investment potential.

Vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic (VEXAS) syndrome is a newly identified disorder caused by an ...

Inmazeb ® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for ...

During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of ...

“Our launch of iron sucrose proves again that we remain committed to pioneering access to more affordable medicines for patients with chronic conditions,” said Keren Haruvi, President Sandoz North ...